QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
OTCMKTS:GTBP

GT Biopharma - GTBP Price Target & Analyst Ratings

$1.34
-0.07 (-4.96%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.27
$1.48
50-Day Range
$1.34
$2.20
52-Week Range
$1.27
$3.89
Volume
91,520 shs
Average Volume
139,456 shs
Market Capitalization
$43.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50

GT Biopharma Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 2 Analyst Ratings

Consensus Analyst Price Target

$11.50
758.21% Upside
High Prediction$18.00
Average Prediction$11.50
Low Prediction$5.00
TypeCurrent
12/6/21 to 12/6/22
1 Month Ago
11/6/21 to 11/6/22
3 Months Ago
9/7/21 to 9/7/22
1 Year Ago
12/6/20 to 12/6/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$11.50$11.50$21.00$25.00
Predicted Upside758.21% Upside359.39% Upside385.74% Upside180.69% Upside
Get GT Biopharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter.


GTBP Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GTBP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

GT Biopharma Stock vs. The Competition

TypeGT BiopharmaMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.66
2.47
Consensus RatingModerate BuyBuyHold
Predicted Upside758.21% Upside584.68% Upside15.21% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
113
63.13%
Underperform Votes
66
36.87%
Avg. Outperform Votes
163
66.26%
Avg. Underperform Votes
83
33.74%
Avg. Outperform Votes
851
68.08%
Avg. Underperform Votes
399
31.92%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/13/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$25.00 ➝ $5.00+105.76%
8/11/2022Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Butler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
1/24/2022B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$26.00 ➝ $18.00+579.24%
(Data available from 12/6/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












GTBP Price Target - Frequently Asked Questions

What is GT Biopharma's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for GT Biopharma stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for GTBP. The average twelve-month price prediction for GT Biopharma is $11.50 with a high price target of $18.00 and a low price target of $5.00. Learn more on GTBP's analyst rating history.

Do Wall Street analysts like GT Biopharma more than its competitors?

Analysts like GT Biopharma less than other Medical companies. The consensus rating for GT Biopharma is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how GTBP compares to other companies.

Do MarketBeat users like GT Biopharma more than its competitors?

MarketBeat users like GT Biopharma less than other Medical companies. 63.13% of MarketBeat users gave GT Biopharma an outperform vote while medical companies recieve an average of 66.26% outperform votes by MarketBeat users.

Does GT Biopharma's stock price have much upside?

According to analysts, GT Biopharma's stock has a predicted upside of 359.39% based on their 12-month price targets.

What analysts cover GT Biopharma?

GT Biopharma has been rated by HC Wainwright in the past 90 days.


Stock Ratings Reports and Tools

This page (OTCMKTS:GTBP) was last updated on 12/6/2022 by MarketBeat.com Staff